AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics. There’s ...

Orient Semiconductor Electronics (OSE) said the global memory industry has shifted decisively into a "seller's market," prompting the company to pass higher costs to customers and accelerate capacity ...

It was 2008, and Father Susai Jesu was behind the wheel on a lonely highway in northern Saskatchewan. He had recently moved from India to work in remote Indigenous communities. He was a world away ...

JERUSALEM — Preliminary findings from the investigation into the site where the body of Jesus Christ is traditionally believed to have been buried appear to confirm that portions of the tomb ...

OSE Immunotherapeutics (OTC:ORPOF) has announced a leadership transition following a decision by its board of directors. The company terminated Nicolas Poirier’s position as CEO and appointed Marc Le ...

Nantes, August 25, 2025, 7:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders’ Meeting, to be held on September 30, ...

Mohsen Baqery is a Guide Staff Writer from Turkey. With a passion for gaming that borders on obsession, Mohsen thrives on guiding fellow gamers through the most challenging obstacles while exploring ...

Cor Jesu players, from left, Roz Doherty, Maddie DiMaria, and Malena Anic, celebrate a goal by Anic in the second half, as St. Dominic defender Madison McGhee (21) expresses her frustration. Cor Jesu ...

No fewer than four popular gospel ministers, including Evangelist Ayodeji David, popularly known as Kekere Jesu, Evangelist Iyanu Joseph, Opeyemi Adesina and Monjolajesu Oluwapamilerin have been ...

Four popular Nigerian gospel ministers, including Evangelist Ayodeji David, popularly known as Kekere Jesu, lost their lives in a fatal motor accident along the Ikorodu–Sagamu Road in Ogun State. The ...

NANTES, France - March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...

An Oxford-based venture capital firm has received £15 million in investment. Aviva Investors, the global asset management business of Aviva, has injected the money into Oxford Science Enterprises (OSE ...